Optimization of culture conditions for production of pneumococcal capsular polysaccharide type IV

Kim, S. N.; Min, Kyungseok; Choi, In-Hwa; Kim, S. W.; Pyo, Suhkneung; Rhee, Dong Kwon

doi:10.1007/bf02976885

Cited by 9 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although fractional DoE cannot be used for finding the optimal concentration of medium compounds, it allowed us to establish a new and more economical culture medium by performing 12 bioreactor experiments instead of the 20 needed for a complete 2 4 DoE with four central points. The novel medium was used in a fed-batch strategy, resulting in a higher level of PS1 production than that of the initial Casamino-acid-containing medium as well as those of other media reported in the literature: 10 times higher than that obtained by Kim et al (1996) using a culture medium of animal origin not recommended for vaccine production, and approximately 8 times higher than that obtained by Yavordios and Cousin (1983). In addition to yielding high PS1 concentrations and productivity, the new culture medium fulfills the regulatory requirements for manufacturing human injectable products (WHO 2003), because Phytone is entirely of animal-free origin.…”

Section: Discussionmentioning

confidence: 84%

Capsular polysaccharide production by Streptococcus pneumoniae serotype 1: from strain selection to fed-batch cultivation

Marthos

Ferri

Figueiredo

et al. 2015

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Streptococcus pneumoniae is a human pathogen largely transmitted by aerosols. Vaccines are the main strategy against this pathogen, and the capsular polysaccharide (PS) is its major antigen. S. pneumoniae serotype 1 is associated with large outbreaks and epidemics of invasive diseases. The aims of this work were to screen serotype 1 strains to identify the best PS1 producer, evaluate three peptones for PS1 production, investigate the effects of culture medium components using a design of experiments (DoE), a statistic tool for optimization, and propose a new medium/cultivation strategy. After flask cultivation of nine strains, two that produced high PS1 and biomass values were chosen for further evaluation in the bioreactor, and ST595/01 was chosen as the best PS1 producer strain. Among the peptones tested (Casamino acids, Soytone, and Phytone), the highest PS1 production (298 mg/L) was reached with Phytone. Next, DoE (2(4-1)) was performed to evaluate the effects of yeast extract (YE), Phytone, L-asparagine (Asn), and L-glutamine (Gln), yielding the following results: Phytone presented positive effects (p < 0.05) for maximum production of biomass, PS1, acetate, and lactate; YE showed positive effects for biomass and acid production (p < 0.05); Gln exerted a minor positive effect on PS1 yield factor on glucose (p < 0.1); and Asn presented only an effect on acetate production (p < 0.1). Hence, a new culture medium was formulated based on Phytone, YE, and glucose, and batch and fed-batch cultivations were evaluated. The fed-batch cultivation showed almost 2 times the biomass and 2.5 times the PS1 production as the batch culture, and 8-10 times higher PS1 production than has been previously reported.

show abstract

Section: Discussionmentioning

confidence: 84%

Capsular polysaccharide production by Streptococcus pneumoniae serotype 1: from strain selection to fed-batch cultivation

Marthos

Ferri

Figueiredo

et al. 2015

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…A partially defined culture medium for Streptococcus pneumoniae was described in 1942 and since then, several authors (Hoeprich, 1957;Adams and Roe, 1944) have improved its formulation, but they all maintained casein or soy hydrolyzate as the nitrogen and carbon source (Van De Rijn and Kessler, 1980). In 1996, Kim et al (1996) described a similar defined medium for the culture of S. pneumoniae but to our knowledge it was not until 2015 that a complete chemically defined medium for the cultivation of S. pneumoniae serotype 1 was described, by our group (Texeira et al, 2015). A novel culture medium free of serum and animal component requires a considerable development effort to provide a formulation capable of supporting microbial production at the desired levels.…”

Section: Introductionmentioning

confidence: 99%

Economic Evaluation of Streptococcus Pneumoniae Culture Media

Morais¹,

Suárez²

2016

American Journal of Biochemistry and Biotechnology

View full text Add to dashboard Cite

Streptococcus pneumoniae, a major bacterial pathogen worldwide, requires a complex medium for culture, which complicates harvesting of antigens for vaccine production. Here we present an economic evaluation of factors affecting the production cost of a chemically defined medium for the scale up of fermentation of S. pneumoniae, compared with the most traditional fermentation media. A basic laboratory-scale experiment of 1 L and an industrial-scale production of 100 L were assumed. The economic analysis results show that at 1 L lab-scale the Chemically Defined Medium (CDM) is the most expensive (US$35/L) compared to Tryptic Soy Broth medium (TSB) and Tryptic Soy Vegitone medium (TSBv),

show abstract

“…Massaldi et al [2010] observed different amounts of the capsule production in three different strains of S. pneumoniae serotype 14. Furthermore, capsule production of S. pneumoniae serotype 4 was dependent on the initial pH of the cultivation medium [Kim et al, 1996]. S. pneumoniae is a lactic acid bacterium, and lactate is its primary metabolic byproduct.…”

Section: Introductionmentioning

confidence: 99%

Recent Approaches in Vaccine Development against Streptococcus pneumoniae

Tarahomjoo

2014

Microb Physiol

View full text Add to dashboard Cite

Streptococcuspneumoniae is a major cause of morbidity and mortality among children under 5 years of age worldwide. Vaccines have long been used for protection against pneumococcal infections. Capsular polysaccharides of pneumococci are main antigenic components of these vaccines. However, pneumococcal polysaccharide-based vaccines are not able to elicit appropriate immunological responses in young children and cannot induce the immune memory. Thus, pneumococcal conjugate vaccines were developed through chemical coupling of an immunogenic carrier protein to the capsule. The currently available pneumococcal conjugate vaccines elicited protection against the bacterium efficiently. However, these vaccines are expensive to manufacture and have limited serotype coverage. In this mini-review, therefore, we describe approaches attempted by researchers to circumvent the shortcomings of the conjugate vaccines including specifying appropriate cultivation conditions for the production of S. pneumoniae capsular antigens, development of suitable expression systems for the frequently used carrier protein in the conjugate vaccines (cross-reacting material 197), construction of protein-based vaccines, whole-cell vaccines, DNA vaccines, and using antigen delivery vehicles. Future trends in this field are also discussed.

show abstract

Optimization of culture conditions for production of pneumococcal capsular polysaccharide type IV

Cited by 9 publications

References 9 publications

Capsular polysaccharide production by Streptococcus pneumoniae serotype 1: from strain selection to fed-batch cultivation

Capsular polysaccharide production by Streptococcus pneumoniae serotype 1: from strain selection to fed-batch cultivation

Economic Evaluation of <i>Streptococcus Pneumoniae</i> Culture Media

Recent Approaches in Vaccine Development against <b><i>Streptococcus pneumoniae</i></b>

Contact Info

Product

Resources

About